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CLINICAL SCIENCE
Increased fibroblast telomerase expression precedes
myofibroblast a-smooth muscle actin expression in
idiopathic pulmonary fibrosis
Daniel Reis Waisberg, Edwin Roger Parra, Joa˜o Valente Barbas-Filho, Sandra Fernezlian, Vera Luiza
Capelozzi
Faculdade de Medicina da Universidade de Sa˜o Paulo, Department of Pathology, Sa˜o Paulo/SP, Brazil.
OBJECTIVE: This study sought to identify the relationship between fibroblast telomerase expression, myofibroblasts,
and telomerase-mediated regulatory signals in idiopathic pulmonary fibrosis.
METHODS: Thirty-four surgical lung biopsies, which had been obtained from patients with idiopathic pulmonary
fibrosis and histologically classified as usual interstitial pneumonia, were examined. Immunohistochemistry was
used to evaluate fibroblast telomerase expression, myofibroblast a-smooth muscle actin expression and the tissue
expression of interleukin-4, transforming growth factor-b, and basic fibroblast growth factor. The point-counting
technique was used to quantify the expression of these markers in unaffected, collapsed, mural fibrosis, and
honeycombing areas. The results were correlated to patient survival.
RESULTS: Fibroblast telomerase expression and basic fibroblast growth factor tissue expression were higher in
collapsed areas, whereas myofibroblast expression and interleukine-4 tissue expression were higher in areas of
mural fibrosis. Transforming growth factor-b expression was higher in collapsed, mural fibrosis and honeycombing
areas in comparison to unaffected areas. Positive correlations were found between basic fibroblast growth factor
tissue expression and fibroblast telomerase expression and between interleukin-4 tissue expression and
myofibroblast a-smooth muscle actin expression. Negative correlations were observed between interleukin-4
expression and basic fibroblast growth factor tissue expression in areas of mural fibrosis. Myofibroblast a-smooth
muscle actin expression and interleukin-4 tissue expression in areas of mural fibrosis were negatively associated with
patient survival.
CONCLUSION: Fibroblast telomerase expression is higher in areas of early remodeling in lung tissues demonstrating
typical interstitial pneumonia, whereas myofibroblast a-smooth muscle actin expression predominates in areas of
late remodeling. These events seem to be regulated by basic fibroblast growth factor and interleukin-4 tissue
expression, respectively.
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a devastating
chronic fibrosing interstitial pneumonia of unknown etiol-
ogy characterized by excessive collagen deposition and
irreversible remodeling of the lung parenchyma (1,2).
Histopathology typically reveals a pattern of usual inter-
stitial pneumonia (UIP), which is typified by patchy areas of
mural fibrosis interspersed with areas of honeycomb
changes as well as collapsed and normal lung parenchyma
(3). Although the etiology of IPF/UIP remains poorly
understood, fibroblasts are believed to be key effectors cells
(4,5) because they proliferate and form fibroblastic foci,
which are thought to constitute the leading edge of fibrosis
(6). Myofibroblasts, which represent differentiated fibro-
blasts, are located in those areas and are the primary cell
type responsible for extracellular matrix (ECM) synthesis
and tissue remodeling, which leads to the loss of alveolar
function (5). A hallmark of myofibroblast differentiation is
the expression of alpha-smooth muscle actin (a-SMA) (7).
The key factor in IPF pathogenesis may be the alveolar
epithelium, which appears to trigger the fibrotic process due
to an impaired healing capacity (8) that leads to alveolar epi-
thelial cell apoptosis (9). Subsequent epithelial-mesenchymal
crosstalk results in persistently activated myofibroblasts,
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which lead to an aberrant wound healing process (8). Our
group previously demonstrated that the cause of this reduced
alveolar epithelial regenerative capacity may be decreased
telomerase expression in type 2 alveolar epithelial cells (10).
In light of these (10) and other recent findings implicating
telomerase in IPF pathogenesis (11-14), we sought to study
fibroblast telomerase expression in IPF.
Telomerase is a specialized polymerase that adds telomere
repeats to the ends of chromosomes, which compensates for
the telomere loss that normally occurs with each cell division
(15-16). Telomerase therefore increases a cell’s life span and is
essential for unlimited cellular proliferation (16). Bleomycin-
induced lung injury and fibrosis are known to induce
telomerase activity in rat lung fibroblasts, which results in
greater numbers of these cells with increased proliferative
capacity (17). Telomerase induction also regulates fibroblast
differentiation; bleomycin injury-induced telomerase activity
is localized primarily to non-myofibroblasts (17), and the
loss of telomerase activity is associated with myofibroblast
differentiation (18). Furthermore, bFGF (basic fibroblast
growth factor) has been identified as the signal responsible
for fibroblast telomerase activity induction, whereas TGF-b
(transforming growth factor beta), and IL-4 (interleukin-4)
are associated with reduced telomerase activity and the
consequent increase in a-SMA expression leading to myofi-
broblast differentiation (19).
In light of these previous data from rat models of
bleomycin-induced pulmonary fibrosis, which have sug-
gested an interaction between fibroblast telomerase activity,
bFGF, IL-4, TGF-b, and myofibroblast differentiation (17-19),
the current study sought to evaluate the following aims in
patients with IPF: (a) whether telomerase is over-expressed
in fibroblasts in the areas of early and late remodeling in
UIP; (b) the relationship between TGF-b, IL-4, and bFGF
tissue expression, fibroblast telomerase and myofibroblast
a-SMA expression; and (c) the impact of these factors on
patient survival.
MATERIALS AND METHODS
Casuistic design
This study examined 34 open surgical lung biopsies, which
had been obtained from patients with a clinical diagnosis of
IPF (19 men and 15 women; median age: 69 years, range: 49-77
years) and histologically classified as UIP. The histological
diagnosis of UIP was made in accordance with the criteria
outlined in the American Thoracic Society/European Respi-
ratory Society International Multidisciplinary Consensus
Classification of the Idiopathic Interstitial Pneumonias (20).
UIP was characterized by the patchy subpleural and para-
septal distribution of parenchymal injury, with temporal
heterogeneity observed at low magnification (Figure 1A).
Areas of unaffected lung parenchyma with alveolar collapse
and interstitial mononuclear infiltrates were characterized as
collapsed areas (Figure 1B). Areas of septal fibro-myxoid
tissue with fibroblastic foci were characterized as areas of
mural fibrosis (Figure 1C). Irregular cystic air spaces between
bands of fibrous connective tissue were characterized as
honeycombing areas (Figure 1D).
We retrospectively reviewed patients’ charts to collect
smoking history, current status, and pulmonary function
test results. Overall survival was calculated as the time
Figure 1 - Panoramic view showing unaffected areas alternating with fibrous and cystic changes, which characterize the UIP histological
pattern (A,640); collapsed area with alveolar collapse and interstitial mononuclear infiltrates (B,6100); mural fibrosis area with septal
fibromyxoid tissue and fibroblastic foci (C,6100); and honeycombing area with irregular cystic air spaces between bands of fibrous
connective tissue (D,6100). Hematoxylin and eosin staining.
Telomerase in IPF/UIP
Waisberg DR et al.
CLINICS 2012;67(9):1039-1046
1040
between the lung biopsy and the date of last contact or
death. No patient was treated for IPF prior to lung biopsy.
Immunohistochemistry analysis
Immunohistochemical analysis was performed using
commercially available kits to characterize TGF-b (poly-
clonal rabbit, cat Sc-146, 1:1500 dilution, Santa Cruz
Biotechnology Inc., USA), IL-4 (polyclonal rabbit, cat 7919,
1:50 dilution, Santa Cruz Biotechnology Inc., USA), bFGF
(monoclonal bovine anti-FGF- 2/basic FGF, clone bFM-2, cat
05-118, 1:100 dilution, Millipore Inc., USA) a-SMA (mono-
clonal mouse, clone 1A4, cat MO 851, 1:500 dilution, Sigma-
Aldrich Inc., USA) and telomerase (polyclonal rabbit, cat
582005, 1:500 dilution, Calbiochem U.S. EMD Biosciences
Inc., USA) expression.
In brief, the sections were deparaffinized and rehydrated
with Tris-buffered saline (0.0005 mol/L Tris and 0.15M
NaCl, pH 7.6) for 10 minutes. Endogenous peroxidase was
blocked with 3% hydrogen peroxide for 5 minutes. Antigen
unmasking was performed with 10 mM citrate buffer
(pH 6.0); for IL-4, trypsin was also used. Next, the sections
were washed in Tris-buffered saline and incubated with
primary antibodies at the appropriate dilutions overnight at
4˚ to 8 C˚. The Novolink kit (code RE 7280-K, Max Polymer
Detector System, Leica Biosystems Inc., UK) was used as a
secondary antibody. The peroxidase reaction was developed
using 3,3-diaminobenzidine tetrachloride (0.25 mg dis-
solved in 1 mL of 0.02% hydrogen peroxide) for 3 minutes.
Morphometry
TGF-b, IL-4 and bFGF tissue expression were assessed in
10 fields using the point-counting technique in unaffected,
collapsed, mural fibrosis and honeycombing areas of the
UIP biopsies (totaling 40 fields per case) using a 100-point
grid with a known area (62500 mm2) attached to the ocular of
the microscope (21). In each field, at 4006magnification, the
lung tissue area was calculated according to the number of
points within pulmonary tissue as a proportion of the total
grid area. Subsequently, the number of positive cells was
counted. The concentration of immunostained cells was
determined as the overall sum of the number of positive
cells divided by the sum of the respective area. The final
result was expressed as a percentage of the marker
expression in each area for each biopsy.
The same methodology was used to calculate myofibro-
blast a-SMA and fibroblast telomerase expression.
However, immunostained cells were considered to be
positive only when they were observed as morphologically
similar to fibroblasts (i.e., thin cells with an elongated
shape). Interobserver comparisons were performed in 20%
of the slides by two observers (E.R.P. and V.L.C.). The
coefficient of variation for the interobserver error in cell
count was ,5%.
Statistical analysis
The expression of each marker was individually com-
pared in unaffected, collapsed, mural fibrosis and honey-
combing area using paired sample t-tests. The Pearson test
was used to determine the associations between the studied
markers. Cox’s regression model was used to analyze
survival. All analyses were performed using SPSS statistical
software (SPSS Inc., USA, 2009). The statistical significance
was set at the level of p#0.05.
The research protocol was approved by the Ethical and
Scientific Committee at our institution Hospital das Clı´nicas,
Faculdade de Medicina da Universidade de Sa˜o Paulo
(CAPPesq 0731/07).
RESULTS
The mean levels of TGF-b, IL-4 and bFGF tissue expression
as well as the mean levels of myofibroblast a-SMA and
fibroblast telomerase expression are shown in Table 1.
Significant associations between these markers are shown
in Table 2. Briefly, TGF-b expression was higher in collapsed,
mural fibrosis and honeycombing areas in comparison to
unaffected areas (Figure 2 - I). IL-4 and myofibroblast a-SMA
expression were higher in mural fibrosis areas (Figure 2 - II
and IV), and bFGF and fibroblast telomerase expression were
highest in collapsed areas (Figure 2 - III and V). No significant
myofibroblast a-SMA expression, fibroblast telomerase
expression or IL-4 tissue expression were found in unaffected
areas. Positive correlations were observed between bFGF
tissue expression and fibroblast telomerase expression and
between IL-4 tissue expression and myofibroblast a-SMA
expression. A negative correlation was observed between IL-
4 and bFGF tissue expression in areas of mural fibrosis.
The Cox proportional hazard model analysis of survival
time identified four variables that were associated with
survival (model likelihood ratio = 26.11; Chi-square = 13.74;
p = 0.01): age greater than 68 years (Odds Ratio [OR] = 2.44,
95% Confidence Interval [CI]: 0.35 – 16.77, p = 0.03); full vital
capacity (FVC) greater than 66% of predicted FVC
(OR = 0.94, 95% CI:0.86–1.03, p = 0.02); myofibroblast a-
SMA expression in mural fibrosis areas higher than 8.55%
(OR = 4.84, 95% CI:0.57–41.03, p = 0.04); and IL-4 tissue
expression in mural fibrosis areas higher than 13.9%
(OR = 10.1, 95% CI:1.08–94.43, p = 0.04). Patients with myofi-
broblast a-SMA expression lower than 8.55% and those with
IL-4 tissue expression lower than 13.9% in areas of mural
fibrosis exhibited better survival (Figure 3).
DISCUSSION
In the present study, we investigated myofibroblast a-
SMA and fibroblast telomerase expression as well as related
regulatory signals (TGF-b, IL-4, bFGF) involved in different
stages of the fibrotic process of UIP/IPF using immunohis-
tochemistry. Fibroblast telomerase expression was higher in
areas of early remodeling and was associated with bFGF
tissue expression, whereas myofibroblast a-SMA expression
was higher in areas of late remodeling and was associated
with IL-4 tissue expression. No significant association was
found for TGF-b, which was highly expressed in collapsed,
mural fibrosis and honeycombing areas. Noticeably, myofi-
broblast a-SMA expression and IL-4 tissue expression in
mural fibrosis areas were associated with patient survival.
There is compelling evidence from both experimental and
clinical studies to suggest the increased proliferative
capacity of lung fibroblasts in cases of IPF. Jordana et al.
demonstrated that primary lung fibroblasts derived from
IPF patients proliferated more rapidly than did fibroblasts
extracted from normal lungs (22), and Zhang and colleagues
demonstrated similar results in fibroblasts isolated from
bleomycin-induced pulmonary fibrosis (23). Telomerase
expression may play a role in the mechanism responsible
for these findings, as demonstrated by the study of Nozaki
et al. (17), which showed that telomerase activity is induced
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in the affected lung tissue and isolated lung fibroblasts from
rats with bleomycin-induced pulmonary fibrosis in a time-
dependent manner. The activity was observed only during
the period of active fibrosis, and its maximal values were
coincident with the peak of fibrosis. Hence, increased levels
of telomerase may contribute to the expansion of the
fibroblast population by enhancing their proliferative
capacity and extending their life span.
A growing body of evidence has demonstrated that lung
fibroblasts in pulmonary fibrosis are heterogeneous with
respect to phenotype and behavior (4,5). Myofibroblasts are a
unique subpopulation of fibroblasts that share features with
smooth cells, as they are contractile and express a-SMA.
These large cells present a distinctive aggressive phenotype
and are believed to be the main cell type responsible for
collagen accumulation and tissue remodeling in IPF (5).
However, myofibroblasts grow markedly more slowly than
intermediate or small-sized fibroblast (24). This differing
proliferative potential and phenotype may be due to
telomerase activity, as this activity was detected primarily
in non-myofibroblasts in the study from Nozaki et al. (17).
Another study from the same group further clarified this
potential link between telomerase expression and myofibro-
blast differentiation (18); using the same bleomycin-induced
pulmonary fibrosis rat model, they demonstrated that the
inhibition of fibroblast telomerase activity led to increased a-
SMA expression, which represents a marker of myofibroblast
differentiation, whereas the induction of telomerase activity
inhibited a-SMA expression. These results suggest that the
loss of telomerase activity is closely related to myofibroblast
differentiation, which is suppressed by telomerase expres-
sion. In the present study, we found that fibroblast telomerase
expression was higher in areas of early remodeling, whereas
myofibroblast a-SMA expression was higher in areas of late
remodeling. This finding may also provide evidence for the
influence of telomerase expression on fibroblast differentia-
tion. Interestingly, fibroblast differentiation is reportedly
higher in cells obtained from early fibrosis as compared to
cells from dense fibrosis (25), and these findings may also be
explained by differences in telomerase expression.
Another study from Liu et al. examined the signals
responsible for the induction of telomerase activity in the
bleomycin-induced pulmonary fibrosis rat model (19). bFGF
was shown to induce telomerase activity in fibroblasts from
both control and bleomycin-treated lungs, but IL-4 and TGF-
b inhibited telomerase activity and were accompanied by a-
SMA expression. Similar correlations were observed in the
present study; however, we analyzed IPF/UIP human cases.
The only exception was TGF-b, which showed no correlation
with fibroblast telomerase or myofibroblast a-SMA expres-
sion, even though it was highly expressed in all examined
areas. This cytokine is reported to play a key role in IPF
pathogenesis, as it is one of the more potent inducers of
collagen deposition (26). A major role of TGF-b involves
mediating the transition of quiescent fibroblasts into cells
with an ‘‘activated’’ phenotype (27), which is consistent with
fibroblast-to-myofibroblast differentiation (5). The fact that
higher TGF-b expression was observed in the epithelium of
Table 2 - Significant correlations between each marker
for each studied area.
Variables Areas
Correlation
Coefficient p-value
bFGF and
telomerase
Collapsed 0.41 0.03
Mural Fibrosis 0.43 0.02
Honeycombing 0.62 0.01
IL-4 and a-SMA Collapsed 0.39 0.05
Mural Fibrosis 0.60 0.01
Honeycombing 0.62 0.01
BFGF and IL-4 Mural Fibrosis -0.63 0.01
Table 1 - Mean levels of TGF-b, IL-4 and bFGF tissue expression and mean levels of myofibroblast a-SMA and fibroblast
telomerase expression in each studied area. For tissue expression, all immunostained cells were considered to be
positive. For fibroblasts expression, only immunostained cells with a morphological similarity to fibroblasts (thin cells
with an elongated shape) were considered to be positive. Abbreviations: U, unaffected areas; C, collapsed areas; MF,
mural fibrosis areas; and H, honeycombing areas.
Marker Unaffected (U) Collapsed (C) Mural Fibrosis (MF) Honeycombing (H) Statistical analysis
TGF-b 9.19¡2.16 19.63¡5.70 16.48¡4.11% 17.08¡4.52% U6C: p=0.01*
U6MF: p=0.01*
U6H: p=0.01*
C6MF: p=0.13
C6H: p=0.51
MF6H: p=0.22
IL-4 0.0¡0.0 3.27¡5.48% 14.03¡6.02% 7.91¡4.04% C6MF: p,0.01*
C6H: p,0.01*
MF6H: p,0.01*
bFGF 10.57¡6.24 15.50¡4.99% 11.62¡3.62% 12.21¡4.68% U6C: p=0.01*
U6MF: p=0.72
U6H: p=0.31
C6MF: p=0.02*
C6H: p=0.03*
MF6H: p=0.65
Myofibroblast
a-SMA
0.0¡0.0 9.02¡2.92% 5.25¡5.14% 5.21¡2.13% C6MF: p,0.01*
C6H: p,0.92
MF6H: p,0.01*
Fibroblast
Telomerase
0.0¡0.0 6.76¡1.31% 5.26¡1.13% 5.01¡1.14% C6MF: p=0.04*
C6H: p=0.03*
MF6H: p=0.19
Area (mean ¡ Standard Deviation).
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collapsed areas may be evidence of epithelial-mesenchymal
crosstalk that results in the persistent activation of fibroblasts.
This scenario occurs in the context of recurrent injury to the
alveolar epithelium, which leads to an inability to re-
epithelialize the denuded basement membrane due to the
impaired healing capacity of the alveolar epithelium (8,28).
To evaluate clinical impact and establish the relevancy of
these findings to the evolution of the patients, telomerase
activity and the levels of profibrotic cytokines and growth
factors were evaluated as a function of patient survival.
Multivariate analysis demonstrated a high risk of death for
patients with IPF, low FVC, high myofibroblast a-SMA
Figure 2 - Tissue TGF-b (I), IL-4 (II) and bFGF expression (III), myofibroblast a-SMA expression (IV), and fibroblast telomerase expression
(V) in collapsed (A), mural fibrosis (B) and honeycomb (C) areas, 100X. FF, fibroblast foci; MF, mural fibrosis; HC, honeycomb.
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Figure 3 - Cox multivariate analysis plots of survival probability versus follow-up time in months for patients .68 years with FVC,66%.
Patients with myofibroblast a-SMA expression lower than 8.55% (A) or with IL-4 tissue expression lower than 13.9% (B) in areas of
mural fibrosis appear as the top curve.
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expression (OR = 4.84) or IL-4 tissue expression (OR = 10.1)
in mural fibrosis areas. In fact, an increase in the number of
fibroblast foci, which represent the primary loci of myofi-
broblasts expressing a-SMA, has already been shown to be
associated with worsened prognosis (6,29). Interleukin-4 is a
fibrotic cytokine that potently induces TGF-b production by
pulmonary fibroblasts and directly stimulates these cells to
produce collagen in vitro, which leads to increased ECM
synthesis (30,31). IL-4 is generally produced by T lympho-
cytes, although it may be produced by different types of
inflammatory cells, such as eosinophils and mast cells (32,33).
It is worth noting that IL-4 promotor gene polymorphisms
have been shown to have a pathogenic role in the etiology
and pathogenesis of IPF (34). The predominance of IL-4
tissue expression in areas of late remodeling in IPF/UIP, as
observed in our study, has also been described previously
(35). Our results are therefore consistent with these
studies.
As in bleomycin-induced lung fibrosis, the expansion of
the lung fibroblast population occurs before the posterior
emergence of myofibroblasts, and the fact that telomerase is
selectively induced in fibroblasts indicates that telomerase
participates in the pathogenesis of fibrosis at a stage prior to
the differentiation of fibroblasts to myofibroblasts (19).
Therefore, these telomerase-positive fibroblasts may repre-
sent an intermediate activated phenotype between quiescent
fibroblasts and their differentiation to myofibroblasts (18).
Similar assumptions for IPF/UIP can be made when
analyzing our results. We observed a spatial relationship
between fibroblast telomerase expression and bFGF tissue
expression in areas of early remodeling and between
myofibroblast a-SMA expression and IL-4 tissue expression
in areas of late remodeling. Therefore, we hypothesize that
the apoptosis of alveolar epithelial cells results in persistent
activation of quiescent fibroblasts via bFGF production,
which is characterized by increased fibroblast telomerase
expression. This process would enhance fibroblast replica-
tive capacity and increase the numbers of these cells,
leading to the formation of fibroblast foci. The early stage
of remodeling would therefore be primarily associated with
the expansion of the fibroblast population. This phenom-
enon would then be followed by a decrease in fibroblast
telomerase expression caused by IL-4 production, which
would result in fibroblast differentiation into myofibro-
blasts. These cells exhibit a strong capacity for ECM
synthesis and deposition and would characterize the late
remodeling process and fibrosis establishment.
We conclude that fibroblast telomerase expression is
higher in the areas of early remodeling in UIP/IPF, whereas
myofibroblast a-SMA expression predominates in areas of
late remodeling, and these events seem to be regulated by
bFGF and IL-4 tissue expression, respectively. Moreover, a-
SMA and IL-4 expression in areas of mural fibrosis in UIP/
IPF may represent surrogate markers for patient prognosis.
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